Evidence map›Paper›PMID 41798215›Full record

ArticleAnnals of clinical epidemiology2026

Overview of Immunotherapy Administration for Miller Fisher Syndrome in Japan: A Nationwide Retrospective Cohort Study.

Satoshi Kodama, Mitsuhiro Kainaga, Shotaro Aso, Taisuke Jo, Yohei Hashimoto, Hiroki Matsui, Hideo Yasunaga, Yuichiro Shirota, Masashi Hamada, Kiyohide Fushimi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Satoshi KodamaDepartment of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mitsuhiro KainagaDepartment of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shotaro AsoDepartment of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Taisuke JoDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Japan.
Yohei HashimotoSave Sight Institute, The Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Hiroki MatsuiDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Japan.
Hideo YasunagaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Japan.
Yuichiro ShirotaDepartment of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masashi HamadaDepartment of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kiyohide FushimiDepartment of Health Policy and Informatics, Institute of Science Tokyo Graduate School, Tokyo, Japan.
Tatsushi TodaDepartment of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMiller Fisher syndrome (MFS) is typically associated with a benign course and spontaneous recovery. However, immunotherapies such as intravenous immunoglobulin (IVIG) and plasma exchange (PE) are often administered for this condition because of the potential for clinical deterioration. We aimed to evaluate the real-world use of immunotherapies in MFS management using a nationwide Japanese database.

methodsWe conducted a retrospective cohort study between April 2014 and March 2020 using the Japanese Diagnosis Procedure Combination database. Patient demographics and treatment modalities were described. Outcomes included length of hospital stay, in-hospital mortality, hospitalization cost, and activities of daily living defined by the Barthel index score.

resultsWe identified 1,595 patients with MFS. Of these, 999 (62.6%) received immunotherapy (including IVIG for 908 [56.9%] patients, intravenous methylprednisolone for 219 [13.7%] patients, and PE for 18 [1.8%] patients). In patients with and without immunotherapy, the median length of hospital stay was 18 and 12 days, in-hospital mortality was 0.7% and 0.2%, median total hospitalization costs were ¥1,660,200 and ¥549,375, and the proportions of Barthel index score of 95-100 at discharge were 75.3% and 75.2%, respectively.

conclusionOur findings highlight the widespread use of immunotherapies for MFS in Japan despite its generally favorable natural course.

Indexed as

Bickerstaff’s brainstem encephalitisGuillain–Barré syndromeintravenous immunoglobulinplasma exchange

Identifiers

PMID41798215
PMCPMC12962335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.